These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical toxicity of cytokines used as haemopoietic growth factors. Vial T; Descotes J Drug Saf; 1995 Dec; 13(6):371-406. PubMed ID: 8652081 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. Hübel K; Dale DC; Liles WC J Infect Dis; 2002 May; 185(10):1490-501. PubMed ID: 11992286 [TBL] [Abstract][Full Text] [Related]
4. TNF-alpha release from human peripheral blood mononuclear cells to predict the proinflammatory activity of cytokines and growth factors. Oshiro Y; Morris DL J Pharmacol Toxicol Methods; 1997 Feb; 37(1):55-9. PubMed ID: 9086289 [TBL] [Abstract][Full Text] [Related]
5. Autoimmune aspects of cytokine and anticytokine therapies. Krause I; Valesini G; Scrivo R; Shoenfeld Y Am J Med; 2003 Oct; 115(5):390-7. PubMed ID: 14553875 [TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations. Wadhwa M; Meager A; Dilger P; Bird C; Dolman C; Das RG; Thorpe R Immunology; 2000 Jan; 99(1):113-23. PubMed ID: 10651949 [TBL] [Abstract][Full Text] [Related]
7. [Cytokines in the treatment of blood diseases]. Robak T Acta Haematol Pol; 1995; 26(2 Suppl 1):72-8. PubMed ID: 7544526 [TBL] [Abstract][Full Text] [Related]
8. [Cutaneous side effects of clinically relevant cytokine therapies]. Trefzer U; Hofmann M; Sterry W Dtsch Med Wochenschr; 2003 Aug; 128(34-35):1782-7. PubMed ID: 12934174 [No Abstract] [Full Text] [Related]
9. Immune-mediated complications during interferon therapy in hematological patients. Raanani P; Ben-Bassat I Acta Haematol; 2002; 107(3):133-44. PubMed ID: 11978934 [TBL] [Abstract][Full Text] [Related]
10. Selective correlation of interferon-gamma, tumour necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor with immunoglobulin G1 and immunoglobulin G3 subclass antibody in leprosy. Hussain R; Kifayet A; Dojki M; Dockrell HM Immunology; 1999 Oct; 98(2):238-43. PubMed ID: 10540222 [TBL] [Abstract][Full Text] [Related]
11. Patients treated with interferon-alpha, interferon-beta, and interleukin-2 have a different thyroid autoantibody pattern than patients suffering from endogenous autoimmune thyroid disease. Schuppert F; Rambusch E; Kirchner H; Atzpodien J; Kohn LD; von zur Mühlen A Thyroid; 1997 Dec; 7(6):837-42. PubMed ID: 9459625 [TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory approaches to augment phagocyte-mediated host defense for treatment of infectious diseases. Liles WC Semin Respir Infect; 2001 Mar; 16(1):11-7. PubMed ID: 11309708 [TBL] [Abstract][Full Text] [Related]
13. Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity. Slight-Webb S; Lu R; Ritterhouse LL; Munroe ME; Maecker HT; Fathman CG; Utz PJ; Merrill JT; Guthridge JM; James JA Arthritis Rheumatol; 2016 Oct; 68(10):2492-502. PubMed ID: 27059145 [TBL] [Abstract][Full Text] [Related]
14. Differential immunostimulating effect of granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and interferon gamma (IFNgamma) after severe trauma. Lendemans S; Kreuzfelder E; Waydhas C; Schade FU; Flohé S Inflamm Res; 2007 Jan; 56(1):38-44. PubMed ID: 17334669 [TBL] [Abstract][Full Text] [Related]
15. [GM-CSF and G-CSF: cytokines in clinical application]. Ruef C; Coleman DL Schweiz Med Wochenschr; 1991 Mar; 121(12):397-412. PubMed ID: 1709294 [TBL] [Abstract][Full Text] [Related]
16. Acute CD4+ T lymphocyte-dependent interleukin-1-driven arthritis selectively requires interleukin-2 and interleukin-4, joint macrophages, granulocyte-macrophage colony-stimulating factor, interleukin-6, and leukemia inhibitory factor. Lawlor KE; Wong PK; Campbell IK; van Rooijen N; Wicks IP Arthritis Rheum; 2005 Dec; 52(12):3749-54. PubMed ID: 16320325 [TBL] [Abstract][Full Text] [Related]
17. Perspectives on the use of cytokines in the management of infectious complications of cancer. Roilides E; Pizzo PA Clin Infect Dis; 1993 Nov; 17 Suppl 2():S385-9. PubMed ID: 7506061 [TBL] [Abstract][Full Text] [Related]
18. Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease. Meager A; Wadhwa M; Bird C; Dilger P; Thorpe R; Newsom-Davis J; Willcox N Immunology; 1999 Jul; 97(3):526-32. PubMed ID: 10447777 [TBL] [Abstract][Full Text] [Related]
19. Effects of interferon-alpha (IFN) on the expression of interleukin 1-beta (IL-1), interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF) in acute myeloid leukemia (AML) blasts. Sissolak G; Hoffbrand AV; Mehta AB; Ganeshaguru K Leukemia; 1992 Nov; 6(11):1155-60. PubMed ID: 1434798 [TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma enhances human eosinophil effector functions induced by granulocyte-macrophage colony-stimulating factor or interleukin-5. Yamaguchi T; Kimura H; Kurabayashi M; Kozawa K; Kato M Immunol Lett; 2008 Jun; 118(1):88-95. PubMed ID: 18440651 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]